Description
Retatrutide is an advanced injectable peptide currently in clinical development, designed to target three major metabolic hormone receptors: GLP-1, GIP, and Glucagon. This triple-receptor activity gives it unmatched potential in fat loss, metabolic regulation, and cardiovascular support – making it the most comprehensive peptide of its kind to date.
Developed by pharmaceutical giant Eli Lilly, Retatrutide is showing superior results compared to well-known peptides like Semaglutide and Tirzepatide. Early trial data reveals record-setting weight loss, improved cardiovascular markers, and promising longevity-enhancing effects, positioning it as a future frontrunner in both medical and performance applications.
Product Summary
Feature | Details |
---|---|
Peptide Name | Retatrutide |
Mechanism | Triple receptor agonist: GLP-1, GIP, Glucagon |
Primary Benefits | Fat loss, cardiovascular health, longevity support |
Administration | Subcutaneous injection (once weekly or split dose) |
Starting Dosage | 0.25mg to 0.5mg per week |
Max Suggested Dosage | Up to 2.5–3mg per week based on tolerance |
Refrigeration Required | Yes, 2°C–8°C after reconstitution |
Suitable For | Fat loss plateaus, metabolic resistance, longevity protocols |
Clinical Status | Phase 2 trials completed; ongoing Phase 3 investigations |
Why Retatrutide Stands Out
Retatrutide represents a major leap forward in peptide-based fat loss. By activating three key hormone pathways instead of one, it delivers powerful results in reducing body fat, improving metabolic markers, and increasing energy expenditure – all while preserving lean muscle.
Initial clinical trials have shown up to 24.2% body weight reduction over just 48 weeks, a result that surpasses even the best-performing GLP-1-based compounds. It also shows promise in lowering blood pressure, reducing non-HDL cholesterol, and aiding in liver and cardiovascular health.
What sets Retatrutide apart is its multi-dimensional action. While GLP-1 and GIP reduce appetite and improve insulin sensitivity, the Glucagon receptor component boosts thermogenesis and fat burning, giving it a unique edge for those looking to lose fat while maintaining muscle and metabolic output.
Whether you’re looking for a powerful fat loss solution, a break through a plateau, or a long-term strategy to support metabolic and hormonal health – Retatrutide offers a robust, science-backed option with evolving data behind it.
Invivo Benefits
Retatrutide doesn’t just work on the surface – it interacts at a cellular and hormonal level to restore balance, increase energy output, and support long-term transformation.
With consistent use, users report improved sleep, fewer cravings, better insulin response, and more stable energy. Its effects go beyond aesthetics, supporting healthy ageing processes such as cellular repair and autophagy – vital components for longevity and wellbeing.
Benefits of Retatrutide
- Clinically Proven Weight Loss
- Up to 24.2% weight reduction in Phase 2 trials
- Ideal for those who didn’t respond well to Semaglutide or Tirzepatide
- Comprehensive Cardiovascular Support
- Reduces non-HDL cholesterol by up to 26.9%
- May assist in lowering risk of heart disease, stroke, and inflammation
- Anti-Ageing & Cellular Repair
- Promotes autophagy and may reduce senescent cell buildup
- Supports mitochondrial health and energy production
- Triple-Receptor Action
- Combines appetite control, fat burning, and energy regulation in one compound
Suggested Use Protocol
- Begin with 0.25mg to 0.5mg per week
- Gradually increase to 2.5mg–3mg per week, based on your response
- Inject subcutaneously once a week, or split into two smaller doses for better tolerance
- Use consistently for 12 to 16+ weeks to achieve optimal outcomes
- Store the reconstituted peptide at 2°C–8°C in the refrigerator
Reviews
There are no reviews yet.